Pharmacotherapy of dyslipidemias in the adult population

Bibliography

• Lipids. In: Scriver CR, Beaudet AL, Sly WS, , editors. The metabolic and molecular bases of inherited disease. 8th edition. Mc Graw Hill, New York; 2001. p. 2705-988
   Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Ignatowski A. Uber die winkung des tierischen eiweisses auf die aorta und die parenchymatose organe der kanichen. Virchows Arch [A] 1909;198:248-70
   Google Scholar
• Kritchevsky D. Laboratory models for atherosclerosis. Adv Drug Res 1974;9:41-53
   PubMedGoogle Scholar
• Russell JC, Proctor SD. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc Pathol 2006;15:318-30
   PubMed Web of Science ®Google Scholar
• Muller C. Angina pectoris in hereditary xanthomatosis. Arch Int Med 1939;64:675-700
   Google Scholar
• Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009;10:109-21
   PubMed Web of Science ®Google Scholar
• Dawber TR. The Framingham Study; the epidemiology of atherosclerotic disease. Harvard University Press, Cambridge; 1980
   Google Scholar
• Toshima H, Koga Y, Keys A. Lessons for science for the Seven Countries Study. A 35-year collaborative experience in cardiovascular disease epidemiology. Springer, Tokyo; 1994
   Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:343-4
   Web of Science ®Google Scholar
• Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-414
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, Consensus Conference Report. Lipoprotein management in patients with cardiometabolic risk. J Am Coll Cardiol 2008;51:1512-24
   PubMed Web of Science ®Google Scholar
• O'Keefe Jr JH, Cordain L, Harris WH, Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-6
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Cannon CP, Morrow DA, Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. A PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol 2005;46:1411-16
   PubMed Web of Science ®Google Scholar
• Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005;112:3368-70
   PubMed Web of Science ®Google Scholar
• Kathiresan S. Lp(a) lipoprotein redux – from curious molecule to causal risk factor. N Engl J Med 2009;361:2573-4
   PubMed Web of Science ®Google Scholar
• Kiechl S, Willeit J. The mysteries of lipoprotein(a) and cardiovascular disease revisited. J Am Coll Cardiol 2010;55:2168-70
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006;260:305-19
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-13
   PubMed Web of Science ®Google Scholar
• De Caterina R, Scarano M, Marfisi RM, Cholesterol-lowering interventions and stroke. Insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010;55:198-211
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
   PubMed Web of Science ®Google Scholar
• Mora S, Glynn RJ, Hsia J, Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia. Circulation 2010;121:1069-77
   PubMed Web of Science ®Google Scholar
• Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 2007;62:879-87
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
   PubMed Web of Science ®Google Scholar
• Strippoli GF, Navaneethan SD, Johnson DW, Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51
   PubMed Web of Science ®Google Scholar
• Fellstrom BC, Jardine AG, Schmieder RE, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45
   PubMed Web of Science ®Google Scholar
• Jarvik GP, Brunzell JD, Motulsky AG. Frequent detection of familial hypercholesterolemia mutations in familial combined hyperlipidemia. J Am Coll Cardiol 2008;52:1554-6
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Graham CA, Young IS, Nicholls DP. Familial combined hyperlipidemia: under-defined and under-diagnosed? Curr Vasc Pharmacol 2008;6:13-22
   PubMed Web of Science ®Google Scholar
• Zuliani G, Vigna GB, Corsini A, Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. Eur J Clin Invest 1995;25:322-31
   PubMed Web of Science ®Google Scholar
• Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007;92:1581-9
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H, Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81
   PubMed Web of Science ®Google Scholar
• Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173:55-68
   PubMed Web of Science ®Google Scholar
• Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;142:105-12
   PubMed Web of Science ®Google Scholar
• Versmissen J, Oosterveer DM, Yazdanpanah M, Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 2002;9:33-9
   PubMedGoogle Scholar
• Bruckert E, Hayem G, Dejager S, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – The PRIMO Study. Cardiovasc Drugs Ther 2005;19:403-14
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association statin safety assessment Task Force. Am J Cardiol 2006;97(Suppl):89C-94C
   Google Scholar
• Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009;22:506-15
   PubMed Web of Science ®Google Scholar
• Brown WV. Safety of statins. Curr Opin Lipidol 2008;19:558-62
   PubMed Web of Science ®Google Scholar
• Kinnman N, Hultcrantz R. Lipid lowering medications and hepatotoxicity. J Intern Med 2001;250:183-5
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-16
   PubMed Web of Science ®Google Scholar
• Kanbay M, Turgut F, Covic A, Goldsmith D. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 2009;22:598-609
   PubMed Web of Science ®Google Scholar
• Bełtowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins – mechanisms and consequences. Curr Drug Saf 2009;4:209-28
   PubMedGoogle Scholar
• Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer's disease. J Neurol Sci 2009;283:230-4
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-63
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
   PubMed Web of Science ®Google Scholar
• Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Brewer Jr HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease: Fibrate Consensus Group. Am J Cardiol 1998;81:912-17
   PubMed Web of Science ®Google Scholar
• Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008;5:542-53
   PubMedGoogle Scholar
• Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol 2010;141:157-66
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010;375:1875-84
   PubMed Web of Science ®Google Scholar
• The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Fievet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Curr Opin Lipidol 2009;20:505-11
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr Opin Cardiol 2009;24:372-9
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007;99:3C-18C
   PubMed Web of Science ®Google Scholar
• Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol 2008;153(Suppl):S68-75
   Google Scholar
• Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Ann Rev Pharmacol Toxicol 2008;48:79-106
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009;20:467-76
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008;101(Suppl):58B-62B
   PubMedGoogle Scholar
• Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events (HPS2-THRIVE). Available from: http://www.controlled-trials.com/ISRCTN29503772. [Accessed 30 June 2010]
   Google Scholar
• Niacin Plus Statin to Prevent Vascular Events (AIM-HIGH). Available from: http://clinicaltrials.gov/show/NCT00120289. [Accessed 30 June 2010]
   Google Scholar
• Wierzbicki AS, Doherty E, Lumb PJ, Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005;21:333-8
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, Akdim F, Stroes ESG, Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Howard WJ. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Nutr Metab Cardiovasc Dis 2010;20:295-300
   PubMed Web of Science ®Google Scholar
• Fleg JL, Mete M, Howard BV, Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-205
   PubMed Web of Science ®Google Scholar
• Meaney A, Ceballos G, Asbun J, The VYtorin on Carotid Intima-media Thickness and Overall Arterial Rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
   PubMed Web of Science ®Google Scholar
• Drazen JM, D'Agostino RB, Ware JH, Ezetimibe and cancer – an uncertain association. N Engl J Med 2008;359:1398-9
   PubMed Web of Science ®Google Scholar
• Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009;10:2973-85
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB. The ‘forgotten' bile acid sequestrants: is now a good time to remember? Am J Ther 2007;14:567-80
   PubMed Web of Science ®Google Scholar
• Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007;8:2569-78
   PubMed Web of Science ®Google Scholar
• Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis 2009;207:16-23
   PubMed Web of Science ®Google Scholar
• Olsson AG. Is high HDL cholesterol always good? Ann Med 2009;41:11-8
   PubMed Web of Science ®Google Scholar
• Yamashita S, Hbujo H, Arai H, Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008;15:292-303
   PubMed Web of Science ®Google Scholar
• Katan MB, Grundy SM, Jones P. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78:965-78
   PubMed Web of Science ®Google Scholar
• Moruisi KG, Oosthuizen W, Opperman AM. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr 2006;25:41-8
   PubMed Web of Science ®Google Scholar
• John S, Sorokin AV, Thompson PD. Phytosterols and vascular disease. Curr Opin Lipidol 2007;18:35-40
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Galli C, Anderson JW, Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 2009;22:244-61
   PubMed Web of Science ®Google Scholar
• Thompson GR; Heart-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198:247-55
   PubMed Web of Science ®Google Scholar
• Thompson GR, Barbir M, Davies D, Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010;208:317-21
   PubMed Web of Science ®Google Scholar
• Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85
   PubMed Web of Science ®Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89:2601-7
   PubMed Web of Science ®Google Scholar
• Lemieux I, Poirier P, Bergeron J, Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology? Can J Cardiol 2007;23(Suppl):23B-31B
   Google Scholar
• Brunzell JD. Hypertriglyceridemia. N Engl J Med 2007;357:1009-17
   PubMed Web of Science ®Google Scholar
• Yang T, Pang CP, Tsang MW, Pathogenic mutations of the lipoprotein lipase gene in Chinese patients with hypertriglyceridemic type 2 diabetes. Hum Mutat 2003;21:453
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-94
   PubMed Web of Science ®Google Scholar
• Mattar M, Obeid O. Fish oil and the management of hypertriglyceridemia. Nutr Health 2009;20:41-9
   PubMedGoogle Scholar
• Zuliani G, Galvani M, Leitersdorf E, The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm Des 2009;15:4087-93
   PubMed Web of Science ®Google Scholar
• Stefanutti C, Di Giacomo S, Vivenzio A, Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif Organs 2009;33:1096-102
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009;32:482-6
   PubMed Web of Science ®Google Scholar
• Neely RD. Who needs a lipid clinic? Int J Clin Pract 2008;62:847-9
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7
   PubMed Web of Science ®Google Scholar
• Bellosta S, Paoletti R, Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(Suppl III):50-7
   Google Scholar
• Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-7
   PubMed Web of Science ®Google Scholar
• Mahley Robert W, Bersot Thomas P. Chapter 35: Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGrawHill, New York; 2006
   Google Scholar
• Pasternak CR, Smith Jr SC, Bairey-Merz CN, ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002;106:1024-8
   PubMed Web of Science ®Google Scholar
• Avis HJ, Hutten BA, Twickler MT, Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr Opin Lipidol 2009;20:484-90
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(Suppl):1K-34K
   PubMed Web of Science ®Google Scholar
• Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep 2009;11:67-70
   PubMed Web of Science ®Google Scholar
• Ladenson PW, Kristensen JD, Ridgway EC, Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16
   PubMed Web of Science ®Google Scholar
• Lowyck I, Fevery J. Statins in hepatobiliary diseases: effects, indications and risks. Acta Gastroenterol Belg 2007;70:381-8
   PubMed Web of Science ®Google Scholar
• Buchwald H, Varco RL, Boen JR, Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998;158:1253-61
   PubMed Web of Science ®Google Scholar
• Rodes-Cabau J, Tardif JC, Cossette M, Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol 2009;104:750-7
   PubMed Web of Science ®Google Scholar
• Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol 2010;21:298-304
   Google Scholar